Spinal Muscular Atrophy management and rare disease healthcare policy
Source:The Hindu ↗
Why It Matters
The management of rare diseases like Spinal Muscular Atrophy involves exorbitant treatment costs, raising serious ethical and policy concerns regarding healthcare equity and resource allocation. Kerala's state-led initiatives (KARE and newborn screening) provide a practical governance case study for addressing healthcare gaps, relevant to GS2 Health policy discussions and GS3 Science & Technology applications.
Summary
The first National Spinal Muscular Atrophy Research and Therapeutic conference (SMArt Con 2025) was inaugurated in Thiruvananthapuram, focusing on the management of rare genetic diseases like SMA. Kerala's proactive steps, such as the Kerala United against Rare Diseases (KARE) initiative and a comprehensive newborn screening programme covering 63 genetic disorders, were highlighted as models for proactive healthcare. Experts at the conference, including representatives from NITI Aayog and the Cure SMA Foundation, emphasized the urgent need for early diagnosis, sustainable financing for highly expensive treatments, and equitable care for patients with rare diseases.
Key Points
- The first-ever National Spinal Muscular Atrophy Research and Therapeutic conference (SMArt Con 2025) was inaugurated in Thiruvananthapuram.
- Kerala Health Minister Veena George highlighted the state's KARE project, which provides comprehensive care and support for rare diseases.
- Kerala is expanding its newborn screening programme to detect up to 63 genetic disorders early.
- The conference emphasized the need for early diagnosis, sustainable financing models for expensive therapies, and equitable access to care.
- NITI Aayog highlighted the commitment of the national health and science ministries toward researching and managing rare diseases.
Important Terms
Spinal Muscular Atrophy (SMA)
A rare genetic neuromuscular disorder caused by SMN1 gene mutations, leading to progressive muscle wasting and weakness. It is a leading genetic cause of infant mortality globally.
UPSC context
Relevant for GS Paper 3 (Science and Technology: Health) and Prelims; tests knowledge of genetic disorders and biotechnology applications.
Kerala United against Rare Diseases (KARE)
A pioneering state initiative launched in 2024 to provide comprehensive, state-funded screening, treatment, and support for patients with rare diseases, including free medication for SMA.
UPSC context
Relevant for GS Paper 2 (Social Justice: Health); exemplifies federal health models and state-level policy interventions for inclusive healthcare.
National Policy for Rare Diseases (NPRD) 2021
A framework launched by the Ministry of Health to categorize rare diseases and provide financial assistance (up to ₹50 lakh) for treatment at designated Centres of Excellence.
UPSC context
Important for GS Paper 2 (Government Policies and Interventions); addresses issues of healthcare financing and the 'Right to Health'.
Cure SMA Foundation of India
A pan-India, parent-led non-profit organization focused on SMA awareness, patient advocacy, and facilitating access to expensive life-saving therapies and clinical trials in India.
UPSC context
Relevant for GS Paper 2 (Role of Civil Society and NGOs); highlights the impact of patient advocacy groups in shaping health policy.
NITI Aayog
India's premier policy think tank that provides strategic direction and policy inputs for the social sector, including recommendations on sustainable financing for high-cost healthcare treatments.
UPSC context
Core for GS Paper 2 (Statutory, Regulatory and Quasi-judicial bodies); tests understanding of institutional roles in development planning and health governance.
Indian Council of Medical Research (ICMR)
The apex body in India for the formulation, coordination, and promotion of biomedical research, critical for clinical guidelines and R&D for rare disease therapies.
UPSC context
Relevant for GS Paper 2 and 3; tests knowledge of India's medical research infrastructure and regulatory responses to health challenges.
Prelims Trap
"The government provides full financial coverage for gene therapies for all rare diseases under NPRD 2021."
NPRD 2021 caps financial support at ₹50 lakhs per patient treated at Centres of Excellence. This falls far short of multi-crore treatments like Zolgensma, relying heavily on digital crowdfunding instead.
Static Concepts Connected
What are the key features of the National Policy for Rare Diseases (NPRD) 2021?
- Categorization: Groups rare diseases into three categories: one-time curative, long-term/lifelong treatment, and diseases with definitive but highly expensive treatments.
- Financial Support: Provides financial support up to ₹50 lakh per patient for treatment at designated Centres of Excellence (CoEs), regardless of BPL status.
- Crowdfunding Mechanism: Mandates the creation of a digital platform to mobilize voluntary corporate and individual donations for expensive treatments.
What is Spinal Muscular Atrophy (SMA) and how is it targeted genetically?
- Genetic Cause: A rare hereditary disorder caused by a mutated or missing SMN1 gene, leading to a severe deficiency of survival motor neuron (SMN) protein.
- Physiological Impact: Causes progressive muscle wasting, weakness, and loss of critical motor functions like breathing and swallowing.
- Gene Replacement: Therapies like Zolgensma work by introducing a new, functional copy of the SMN1 gene directly into the patient's motor neurons using a viral vector.
Cross-Topic Patterns
Health Equity & State-backed Crowdfunding
The astronomical cost of gene therapies bridges S&T with socio-economic policy, making digital crowdfunding platforms a formal, government-backed mechanism in India's public health strategy under the NPRD 2021.
State vs Centre Health Policy Models
Kerala's comprehensive KARE initiative and 63-disease newborn screening serve as an excellent Mains GS2 case study for decentralized, proactive state-led healthcare models outperforming broader national programs.
A Prelims question linking rare genetic diseases (like SMA) with gene therapy mechanisms and NPRD 2021 funding caps is likely in 2026.
Linked PYQs · 4
Linked PYQs · 4
- 2021PrelimsGS1
In the context of hereditary diseases, consider the following statements : 1. Passing on mitochondrial diseases from parent to child can be prevented by mitochondrial replacement therapy either before or after in vitro fertilization of egg. 2. A child inherits mitochondrial diseases entirely from mother and not from father. Which of the statements given above is/are correct?
- 2020MainsGS2
In order to enhance the prospects of social development, sound and adequate health care policies are needed particularly in the fields of geriatric and maternal health care. Discuss.
- 2024MainsGS2
In a crucial domain like the public healthcare system the Indian State should play a vital role to contain the adverse impact of marketisation of the system. Suggest some measures through which the State can enhance the reach of public healthcare at the grassroots level.
- 2021MainsGS2
“Besides being a moral imperative of a Welfare State, primary health structure is a necessary precondition for sustainable development.” Analyze.
